Teacher Retirement System of Texas Sells 447,650 Shares of Hologic, Inc. (NASDAQ:HOLX)

Teacher Retirement System of Texas lessened its position in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 68.9% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 202,233 shares of the medical equipment provider's stock after selling 447,650 shares during the period. Teacher Retirement System of Texas owned approximately 0.09% of Hologic worth $12,492,000 as of its most recent filing with the SEC.

Several other hedge funds also recently bought and sold shares of HOLX. Vontobel Holding Ltd. raised its holdings in shares of Hologic by 34.8% during the first quarter. Vontobel Holding Ltd. now owns 39,475 shares of the medical equipment provider's stock worth $2,438,000 after acquiring an additional 10,185 shares during the period. KBC Group NV increased its holdings in Hologic by 4.1% during the 1st quarter. KBC Group NV now owns 97,233 shares of the medical equipment provider's stock worth $6,006,000 after purchasing an additional 3,857 shares in the last quarter. Allspring Global Investments Holdings LLC raised its stake in shares of Hologic by 45.0% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 296,735 shares of the medical equipment provider's stock valued at $18,214,000 after purchasing an additional 92,132 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Hologic by 12.5% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 30,305 shares of the medical equipment provider's stock valued at $1,858,000 after purchasing an additional 3,366 shares during the period. Finally, Canvas Wealth Advisors LLC lifted its holdings in shares of Hologic by 431.7% in the first quarter. Canvas Wealth Advisors LLC now owns 16,158 shares of the medical equipment provider's stock valued at $940,000 after purchasing an additional 13,119 shares in the last quarter. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, Director Martin D. Madaus purchased 5,445 shares of the company's stock in a transaction dated Wednesday, May 7th. The shares were purchased at an average cost of $55.24 per share, with a total value of $300,781.80. Following the transaction, the director directly owned 5,445 shares in the company, valued at $300,781.80. This trade represents a ∞ increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 1.88% of the company's stock.

Hologic Price Performance

Shares of NASDAQ HOLX traded down $0.57 during mid-day trading on Friday, reaching $64.74. 1,233,581 shares of the company were exchanged, compared to its average volume of 2,373,435. Hologic, Inc. has a 52 week low of $51.90 and a 52 week high of $84.67. The company's 50 day moving average price is $60.71 and its 200 day moving average price is $63.76. The stock has a market capitalization of $14.43 billion, a PE ratio of 27.31, a PEG ratio of 2.37 and a beta of 0.55. The company has a quick ratio of 2.52, a current ratio of 3.24 and a debt-to-equity ratio of 0.54.

Hologic (NASDAQ:HOLX - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The medical equipment provider reported $1.03 EPS for the quarter, topping the consensus estimate of $1.02 by $0.01. The firm had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $1 billion. Hologic had a return on equity of 19.71% and a net margin of 13.83%. The company's quarterly revenue was down 1.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.03 earnings per share. Sell-side analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on HOLX shares. Stephens lowered their price target on shares of Hologic from $77.00 to $70.00 and set an "overweight" rating on the stock in a research note on Tuesday, May 13th. Raymond James Financial restated an "outperform" rating and issued a $71.00 price objective (down previously from $90.00) on shares of Hologic in a report on Friday, May 2nd. Royal Bank Of Canada dropped their target price on Hologic from $75.00 to $70.00 and set a "sector perform" rating on the stock in a report on Friday, May 2nd. Morgan Stanley reduced their price target on Hologic from $77.00 to $65.00 and set an "equal weight" rating for the company in a research report on Monday, May 5th. Finally, Needham & Company LLC restated a "hold" rating on shares of Hologic in a research note on Tuesday, May 27th. Twelve research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Hold" and an average target price of $77.42.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.